FOLH1 and metastatic neoplasm: Targeted therapy designed to selectively bind to prostate cancer cells expressing the prostate-specific membrane antigen (PSMA) presents a promising alternative, particularly for those with widespread metastatic disease and contraindications to chemotherapy.